Teva Pharmaceuticals Logo
US8816242098
883035
TEVA

Teva Pharmaceuticals

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 38,78 (+15,66%). A mediana é € 38,57 (+15,03%).

Comprar
  21
Manter
  21
Vender
  4

  • Teva accelerates pivot to growth as branded drugs and biosimilars drive outlook

    Teva says its 'Pivot to Growth' strategy is entering a faster phase as branded medicines gain momentum, generics stabilize and biosimilars expand. Management highlighted AUSTEDO's potential to exceed $3 billion, AJOVY approaching $1 billion, and UZEDY plus long‑acting olanzapine representing a $1.5–2 billion opportunity. The company has 11 biosimilars on the market with about nine more planned by decade-end and expects to beat its $800 million biosimilars target for 2027 early. Teva also reduced debt, secured investment‑grade ratings ahead of schedule, completed refinancing, and is advancing pipeline assets including ecopipam and duvakitug toward potential 2027 launches. » Mais em finance.yahoo.com


  • S&P upgrades Teva to BBB- after debt reduction and strong branded pipeline

    S&P Global Ratings has upgraded Teva from BB+ to BBB- and raised all of the company’s ratings. The agency cites ongoing debt reduction, stabilization in the generics business and growth of high-margin branded products; leverage is expected to fall from about 4x in the second quarter to the mid-3x range by year-end. S&P expects strong adjusted operating cash flow of $2.3–2.5 billion annually, substantial cost savings through 2027, as well as revenue gains from key brands such as Austedo, Ajovy and Uzedy and important product launches in the coming years. » Mais em de.investing.com


  • Teva asks judge to bar mention of Israeli origin at Humana price-fixing trial

    Teva asked a U.S. judge to prevent insurer Humana from telling jurors the company is Israeli, arguing references to its national origin could prejudice the jury amid strong U.S. emotions over the Gaza war. The Tel Aviv-based drugmaker said national origin is irrelevant to allegations it conspired to inflate generic drug prices and could undermine a fair trial. The U.S. trial is scheduled to begin Sept. 15 and covers claims over drugs including baclofen and propranolol. » Mais em finance.yahoo.com

Em 2017, Teva Pharmaceuticals já distribuiu € 0,66 em dividendos. A última distribuição ocorreu em dezembro de 2017.

Dados financeiros da empresa

No último trimestre, Teva Pharmaceuticals registou receitas de € 3,63 bi e um ganho líquido de -€ 504,7 mi
(EUR) junho de 2026
YoY
Receitas 3,63 bi 2,43%
Ganho bruto 1,89 bi 5,78%
Ganho líquido -504,7 mi 310,95%
EBITDA -16,65 mi 102,99%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 37,44 bi
Número de ações
1,16 bi
Máximo/mínimo de 52 semanas
€ 33,25 - € 15,78
Dividendos Não
Beta
0,87
PER (PE Ratio)
58,25
PEG (PEG Ratio)
0,11
P/VC (PB Ratio)
5,51
P/V (PS Ratio)
2,46

Perfil da empresa

Teva Pharmaceutical Industries Limited, ein Pharmaunternehmen, entwickelt, produziert, vermarktet und vertreibt Generika, Spezialmedikamente und biopharmazeutische Produkte in Nordamerika, Europa und international. Das Unternehmen bietet sterile Produkte, Hormone, hochwirksame Medikamente und zytotoxische Substanzen in verschiedenen Darreichungsformen an, darunter Tabletten, Kapseln, Injektionsmittel, Inhalationsmittel, Flüssigkeiten, transdermale Pflaster, Salben und Cremes. Außerdem entwickelt, produziert und vertreibt das Unternehmen pharmazeutische Wirkstoffe. Darüber hinaus konzentriert sich das Unternehmen auf die Bereiche zentrales Nervensystem, Schmerzen, Atemwege und Onkologie. Zu den Produkten im Bereich des zentralen Nervensystems gehören Copaxone zur Behandlung schubförmiger Formen der Multiplen Sklerose, AJOVY zur vorbeugenden Behandlung von Migräne und AUSTEDO zur Behandlung von Spätdyskinesien und Chorea im Zusammenhang mit der Huntington-Krankheit. Die Produkte des Unternehmens auf dem Atemwegsmarkt umfassen ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler und ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax und AirDuo RespiClick/ArmonAir RespiClick für die Behandlung von Asthma und chronisch obstruktiven Lungenerkrankungen. Zu seinen Produkten auf dem Onkologiemarkt gehören Bendeka, Treanda, Granix, Trisenox, Lonquex und Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited kooperiert mit MedinCell bei der Entwicklung und Vermarktung mehrerer langwirksamer injizierbarer Produkte, einer Risperidon-Suspension für die Behandlung von Patienten mit Schizophrenie. Das Unternehmen wurde 1901 gegründet und hat seinen Hauptsitz in Tel Aviv-Yafo, Israel.

Nome
Teva Pharmaceuticals
CEO
Richard D. Francis
Sede Tel Aviv, ta
EUA
Site
Setor
Cuidados de saúde
Indústria
Produtos farmacêuticos
Entrada em bolsa
16/02/1982
Colaboradores 32.008

Análise aprofundada

Símbolos de ticker

Bolsa Símbolo
NYSE
TEVA
Frankfurt
TEV.F
Düsseldorf
TEV.DU
Hamburg
TEV.HM
London
0LER.L
SIX
TEVA.SW
München
TEV.MU
Wien
TEVA.VI
🍪

Parqet  utiliza cookies. Saber mais